HK Stock Market Move | CARSGEN-B(02171) rose over 7% CT071 research results will be presented at the EHA Annual Meeting. It is expected that CT041 will submit an NDA in the first half of the year.

CARSGEN-B (02171) rose more than 7%, as of the time of publication, rose 7.49% to HK$16.64, with a turnover of HK$25.4024 million. On the news front, KJ Medicine announced earlier that the summary of the research results of the clinical trial (NCT06407947) initiated by researchers using CT071 (an autologous CAR-T cell product targeting GPRC5D) for the treatment of newly diagnosed multiple myeloma (NDMM) has been accepted for presentation at the 2025 European Hematology Association (EHA) annual meeting, to be released during the poster session. The summary and further information will be announced after 15:30 Central European Time on May 14, 2025. In addition, the company announced that the injection of Shuriji Auluncai (product number: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2 protein) has had the summary of the results of the confirmatory Phase II clinical trial (CT041-ST-01, NCT04581473) conducted in China for advanced gastric/esophagogastric junction adenocarcinoma accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) annual meeting. The summary and further information will be announced after May 22, 2025 Eastern Time. Zheshang previously indicated that, according to the company's annual report disclosure, it is expected to submit an NDA for late-stage treatment of GC/GEJ indications in 2025H1, and the company is expected to become the first approved commercialized solid tumor CAR-T therapy. Considering the large number of solid tumor patients, the outlook for the commercialization prospects of CT041 is positive.